Allergy Therapeutics' 1H trading update sees market share gains in all of its major European markets, reflected in strong double digit constant currency revenue growth (+12% vs 1H15 +11%) to deliver 1H revenues (CER) of c.£31.5m (1H15: £28.2m). On a reported basis (i.e. accounting for currency headwinds of c.£2.5m) the company still expects to see 1H growth of +3% to c.£29.0m (1H15: £28.2m) and, on this basis, continues to track in-line with full-year expectation
